Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Epidemiology of Sepsis in Germany: Incidence, Mortality And Associated Costs of Care 2007-2013.

Fleischmann C, Hartmann M, Hartog CS, Welte T, Heublein S, Thomas-Rueddel D, Dennler U, Reinhart K.

Intensive Care Med Exp. 2015 Dec;3(Suppl 1):A50. doi: 10.1186/2197-425X-3-S1-A50. No abstract available.

PMID:
27290058
2.

Hospital Incidence and Mortality Rates of Sepsis.

Fleischmann C, Thomas-Rueddel DO, Hartmann M, Hartog CS, Welte T, Heublein S, Heublein S, Dennler U, Reinhart K.

Dtsch Arztebl Int. 2016 Mar 11;113(10):159-66. doi: 10.3238/arztebl.2016.0159.

3.

p53 determines prognostic significance of the carbohydrate stem cell marker TF1 (CD176) in ovarian cancer.

Heublein S, Page SK, Mayr D, Ditsch N, Jeschke U.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1163-70. doi: 10.1007/s00432-016-2126-3. Epub 2016 Mar 2.

PMID:
26935926
4.

Extra length of stay and costs because of health care-associated infections at a German university hospital.

Arefian H, Hagel S, Heublein S, Rissner F, Scherag A, Brunkhorst FM, Baldessarini RJ, Hartmann M.

Am J Infect Control. 2016 Feb;44(2):160-6. doi: 10.1016/j.ajic.2015.09.005.

PMID:
26521700
5.

PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer.

Fan SJ, Snell C, Turley H, Li JL, McCormick R, Perera SM, Heublein S, Kazi S, Azad A, Wilson C, Harris AL, Goberdhan DC.

Oncogene. 2016 Jun 9;35(23):3004-15. doi: 10.1038/onc.2015.363. Epub 2015 Oct 5.

PMID:
26434594
6.

Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.

Heublein S, Mayr D, Meindl A, Angele M, Gallwas J, Jeschke U, Ditsch N.

PLoS One. 2015 Jun 1;10(6):e0127072. doi: 10.1371/journal.pone.0127072. eCollection 2015.

7.

Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients.

Heublein S, Mayr D, Egger M, Karsten U, Goletz S, Angele M, Gallwas J, Jeschke U, Ditsch N.

J Exp Clin Cancer Res. 2015 May 19;34:50. doi: 10.1186/s13046-015-0152-7.

8.

Glycosyltransferases as marker genes for the quantitative polymerase chain reaction-based detection of circulating tumour cells from blood samples of patients with breast cancer undergoing adjuvant therapy.

Kölbl AC, Hiller RA, Ilmer M, Liesche F, Heublein S, Schröder L, Hutter S, Friese K, Jeschke U, Andergassen U.

Mol Med Rep. 2015 Aug;12(2):2933-8. doi: 10.3892/mmr.2015.3732. Epub 2015 May 5.

PMID:
25955084
9.

The G-protein-coupled estrogen receptor (GPER/GPR30) in ovarian granulosa cell tumors.

Heublein S, Mayr D, Friese K, Jarrin-Franco MC, Lenhard M, Mayerhofer A, Jeschke U.

Int J Mol Sci. 2014 Aug 27;15(9):15161-72. doi: 10.3390/ijms150915161.

10.

Strong correlation between N-cadherin and CD133 in breast cancer: role of both markers in metastatic events.

Bock C, Kuhn C, Ditsch N, Krebold R, Heublein S, Mayr D, Doisneau-Sixou S, Jeschke U.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1873-81. doi: 10.1007/s00432-014-1750-z. Epub 2014 Jun 25.

PMID:
24962344
11.

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients.

Kirn V, Shi R, Heublein S, Knabl J, Guenthner-Biller M, Andergassen U, Fridrich C, Malter W, Harder J, Friese K, Mayr D, Jeschke U.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1681-7. doi: 10.1007/s00432-014-1729-9. Epub 2014 Jun 8.

PMID:
24908329
12.

ESR1 promoter methylation in squamous cell cervical cancer.

Kirn V, Zaharieva I, Heublein S, Thangarajah F, Friese K, Mayr D, Jeschke U.

Anticancer Res. 2014 Feb;34(2):723-7.

PMID:
24511005
13.

Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176).

Andergassen U, Kölbl AC, Zebisch M, Heublein S, Hutter S, Ilmer M, Schindlbeck C, Friese K, Jeschke U.

Histol Histopathol. 2014 Jul;29(7):913-23. Epub 2014 Jan 8.

PMID:
24399516
14.

Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.

Lenhard M, Heublein S, Kunert-Keil C, Vrekoussis T, Lomba I, Ditsch N, Mayr D, Friese K, Jeschke U.

BMC Cancer. 2013 Dec 30;13:616. doi: 10.1186/1471-2407-13-616.

15.

Significance of the tumor protease cathepsin D for the biology of breast cancer.

Dian D, Heublein S, Wiest I, Barthell L, Friese K, Jeschke U.

Histol Histopathol. 2014 Apr;29(4):433-8. Epub 2013 Nov 22. Review.

PMID:
24265119
16.

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

Heublein S, Grasse K, Hessel H, Burges A, Lenhard M, Engel J, Kirchner T, Jeschke U, Mayr D.

BMC Cancer. 2013 Oct 18;13:483. doi: 10.1186/1471-2407-13-483.

17.

The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.

Heublein S, Mayr D, Vrekoussis T, Friese K, Hofmann SS, Jeschke U, Lenhard M.

PLoS One. 2013 Aug 9;8(8):e71791. doi: 10.1371/journal.pone.0071791. eCollection 2013.

18.

Expression and function of galectins in the endometrium and at the human feto-maternal interface.

Jeschke U, Hutter S, Heublein S, Vrekoussis T, Andergassen U, Unverdorben L, Papadakis G, Makrigiannakis A.

Placenta. 2013 Oct;34(10):863-72. doi: 10.1016/j.placenta.2013.07.005. Epub 2013 Jul 30. Review.

PMID:
23911101
19.

Multicentric and multifocal versus unifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology.

Weissenbacher T, Hirte E, Kuhn C, Janni W, Mayr D, Karsten U, Rack B, Friese K, Jeschke U, Heublein S, Dian D, Ditsch N.

BMC Cancer. 2013 Jul 26;13:361. doi: 10.1186/1471-2407-13-361.

20.

Macrophages: are they involved in endometriosis, abortion and preeclampsia and how?

Hutter S, Heublein S, Knabl J, Andergassen U, Vrekoussis T, Makrigiannakis A, Friese K, Mayr D, Jeschke U.

J Nippon Med Sch. 2013;80(2):97-103. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk